Pharmaceutical News

RSS

G-CON completes delivery and installation of POD system in PaxVax's GMP production facility

G-CON today announced the completed delivery and installation of the ground-breaking POD system in PaxVax's licensed GMP production facility based in San Diego, California where PaxVax manufactures innovative and socially responsible oral vaccines against infectious diseases.

19 Jan 2013

Ban on thiomersal in vaccines would harm global immunization efforts

"Government representatives are meeting in Geneva this week to decide whether to introduce a global ban on mercury that could include thiomersal, a mercury-based preservative that has been used in some vaccine manufacturing since the 1930s to prevent bacterial or fungal contamination of multidose vials of vaccine," Seth Berkley, a medical epidemiologist and chief executive of the GAVI Alliance, writes in a New York Times opinion piece.

19 Jan 2013

EMA adopts positive opinion for Pfizer’s bosutinib conditional approval in the EU

Pfizer Inc. announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion regarding the conditional marketing authorization of bosutinib in the European Union for the treatment of adult patients with chronic phase (CP), accelerated phase (AP), and blast phase (BP) Philadelphia chromosome positive chronic myelogenous leukemia previously treated with one or more tyrosine kinase inhibitor(s) (TKIs) and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options.

19 Jan 2013

New method may help predict response to chemotherapy for bowel cancer

Scientists at the Royal College of Surgeons in Ireland (RCSI) and Beaumont Hospital have developed a new method of predicting which patients with bowel (colorectal) cancer will respond effectively to chemotherapy. The results of this study are published in the current issue of the prestigious Cancer Research journal.

19 Jan 2013

FDA approves Allergan’s BOTOX to treat overactive bladder

Allergan, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved BOTOX (onabotulinumtoxinA) for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency and frequency in adults who have had an inadequate response to or are intolerant of an anticholinergic medication.

19 Jan 2013

Rite Aid obtains more than 400,000 additional seasonal flu shots

In response to the nationwide flu epidemic and customer demand, Rite Aid Corporation announced today it has obtained more than 400,000 additional seasonal flu shots, which began arriving in stores earlier this week.

19 Jan 2013

New math model may help predict colon cancer resistance to chemotherapy

Scientists may be able to better predict which patients with colorectal cancer will respond to chemotherapy using a new mathematical model that measures the amount of stress required for a cancer cell to die without harming healthy tissue. The results of this study are published in Cancer Research, a journal of the American Association for Cancer Research.

19 Jan 2013

SPARC protein acts much like ibuprofen to heal tissues inflamed by tumors

Cancer researchers are increasingly aware that in addition to genetic mutations in a cancer itself, characteristics of the surrounding tissue can promote or suppress tumor growth. One of these important tissue characteristics is inflammation - most cancers prosper in and attach to inflamed tissue and so many cancers have developed ways to create it.

19 Jan 2013

Survey finds shortage of TB medicines in U.S.; Consequences similar to lack of access in developing countries, advocate says

"More than 80 percent of health departments in the United States that treat tuberculosis [TB] resistant to standard treatment have trouble obtaining the drugs they need to cure the disease, according to a national survey released on Thursday," Reuters reports.

18 Jan 2013

Researchers identify signaling pathway used by malarial parasites to destroy host cells

One of the most insidious ways that parasitic diseases such as malaria and toxoplasmosis wreak their havoc is by hijacking their host's natural cellular processes, turning self against self.

18 Jan 2013

Allergan receives FDA approval for Botox to treat overactive bladder

The U.S. Food and Drug Administration today expanded the approved use of Botox (onabotulinumtoxinA) to treat adults with overactive bladder who cannot use or do not adequately respond to a class of medications known as anticholinergics.

18 Jan 2013

Medications often prescribed for PAH could affect heart health of treated patients

A research team with the Faculty of Medicine & Dentistry at the University of Alberta reported findings that significantly improve understanding of how widely used drugs in Pulmonary Arterial Hypertension (PAH) affect the heart health of treated patients.

18 Jan 2013

$ADT increases risk of fracture incidence after treatment completion in men with prostate cancer$

ADT increases risk of fracture incidence after treatment completion in men with prostate cancer

In what is believed to be the first study to describe the impact on men with a 'high' risk of bone fracture who are receiving long-term androgen deprivation therapy (ADT) for prostate cancer, new research from The Cancer Institute of New Jersey shows this population to have a higher fracture incidence following treatment completion.

18 Jan 2013

mTorc1 promotes growth of inflammation-associated colon and gastric cancers

Researchers have identified a complex of proteins that promotes the growth of some types of colon and gastric cancers, and shown that medications that block the function of this complex have the potential to be developed into a new treatment for these diseases.

18 Jan 2013

Sabutoclax appears to selectively target leukemia stem cells that are responsible for relapses

Researchers at the University of California, San Diego School of Medicine have discovered that hard-to-reach, drug-resistant leukemia stem cells (LSCs) that overexpress multiple pro-survival protein forms are sensitive - and thus vulnerable - to a novel cancer stem cell-targeting drug currently under development.

18 Jan 2013

FDA approves Protein Sciences’ Flublok to prevent seasonal influenza

The US Food and Drug Administration has approved Protein Sciences Corporation's vaccine Flublok for the prevention of seasonal influenza in adults 18 to 49 years of age. Diamyd Medical holds about 8 percent of the shares in Protein Sciences Corporation.

18 Jan 2013

Health Canada approves Forest Laboratories’ BYSTOLIC to treat hypertension

Forest Laboratories, Inc. announced today that its Canadian subsidiary, Forest Laboratories Canada Inc. has received a Notice of Compliance from Health Canada for BYSTOLIC (nebivolol) tablets, a once daily beta blocker for the treatment of hypertension.

18 Jan 2013

Stroke patients with PTSD less likely to adhere to treatment regimens

A new survey of stroke survivors has shown that those with post-traumatic stress disorder (PTSD) are less likely to adhere to treatment regimens that reduce the risk of an additional stroke. Researchers found that 65 percent of stroke survivors with PTSD failed to adhere to treatment, compared with 33 percent of those without PTSD.

18 Jan 2013

Octapharma receives FDA approval for Octaplas to treat blood clotting disorders

The U.S. Food and Drug Administration today approved Octaplas, a pooled plasma (human) blood product for the replacement of clotting proteins (coagulation factors) in certain medical conditions where patients have insufficient levels.

18 Jan 2013

Spain approves pSivida’s ILUVIEN to treat chronic diabetic macular edema

pSivida Corp., a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, announced today that the Spanish Agency of Drugs and Medical Devices (Agencia Espanola de Medicamentos y Productos Sanitarios) granted marketing authorization to ILUVIEN for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies.

18 Jan 2013

Pharmaceutical News

G-CON completes delivery and installation of POD system in PaxVax's GMP production facility

Ban on thiomersal in vaccines would harm global immunization efforts

EMA adopts positive opinion for Pfizer’s bosutinib conditional approval in the EU

New method may help predict response to chemotherapy for bowel cancer

FDA approves Allergan’s BOTOX to treat overactive bladder

Rite Aid obtains more than 400,000 additional seasonal flu shots

New math model may help predict colon cancer resistance to chemotherapy

SPARC protein acts much like ibuprofen to heal tissues inflamed by tumors

Survey finds shortage of TB medicines in U.S.; Consequences similar to lack of access in developing countries, advocate says

Researchers identify signaling pathway used by malarial parasites to destroy host cells

Allergan receives FDA approval for Botox to treat overactive bladder

Medications often prescribed for PAH could affect heart health of treated patients

ADT increases risk of fracture incidence after treatment completion in men with prostate cancer

mTorc1 promotes growth of inflammation-associated colon and gastric cancers

Sabutoclax appears to selectively target leukemia stem cells that are responsible for relapses

FDA approves Protein Sciences’ Flublok to prevent seasonal influenza

Health Canada approves Forest Laboratories’ BYSTOLIC to treat hypertension

Stroke patients with PTSD less likely to adhere to treatment regimens

Octapharma receives FDA approval for Octaplas to treat blood clotting disorders

Spain approves pSivida’s ILUVIEN to treat chronic diabetic macular edema

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News